IDEXX in the news

IDEXX Laboratories develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock.

IDEXX Laboratories has seen its share price fall significantly, leading to mixed opinions on whether it is undervalued based on future growth or overvalued considering its current P/E ratio compared to the industry.

IDEXX Laboratories acquired CoVetAI to integrate AI-driven workflow software into its veterinary diagnostics and practice management offerings, aiming to enhance clinical insights and operational efficiency.

IDEXX Laboratories Inc. stock underperformed on Tuesday, falling 2.21% while the broader market gained.

IDEXX Laboratories' stock decreased on October 6, ahead of its Q3 2026 earnings report on November 2, following strong Q2 results that surpassed analyst expectations.

IDEXX Laboratories stock increased in after-hours trading, and the company announced its Q3 2026 results release and the acquisition of CoVetAI.

IDEXX Laboratories' stock was USD 518.39 on October 2, 2026, ahead of its Q3 2026 earnings report on November 2, 2026, after Q2 2026 adjusted EPS of USD 4.27 beat consensus by USD 0.33.

IDEXX benefits from increased pet healthcare spending and strong customer loyalty due to its integrated clinic ecosystem.

IDEXX Laboratories reported 3.66 billion EUR in revenue, primarily from its Companion Animal Group and the United States market.

IDEXX Laboratories will announce its third quarter 2026 financial results on November 2, 2026, followed by an analyst conference call.

IDEXX Laboratories stock remained stable in after-hours trading while the company recently acquired CoVetAI Inc., an AI software provider for veterinary practices.

IDEXX acquired CoVet, an AI platform that automates clinical documentation for veterinary practices, to integrate into its practice-management suite.

IDEXX Laboratories is being evaluated on its veterinary diagnostics' product adoption and execution amidst a defensive market, with investors awaiting specific company evidence to confirm its business trajectory.

FETCH a Cure and IDEXX are collaborating on two November events in Richmond to support pets with cancer through fundraising and awareness campaigns.

IDEXX Laboratories acquired CoVetAI, a veterinary AI platform, to advance pet healthcare innovation.

IDEXX Laboratories acquired CoVetAI, an AI-powered clinical scribe platform for veterinarians, from Chicago Pacific Founders.

Chicago Pacific Founders Pet Fund exited its investment in CoVet after the veterinary AI company was acquired by IDEXX Laboratories.

IDEXX Laboratories' stock increased as the company announced an acquisition of an AI software provider and an expansion of its faecal testing capabilities in the UK.

IDEXX Laboratories' stock rose on September 25, 2026, following strong Q2 results and an acquisition, while maintaining an updated full-year outlook.

IDEXX Laboratories expanded its UK Faecal Dx platform to include taeniid tapeworms, aiming to boost recurring diagnostic revenue and strengthen its market position in veterinary diagnostics.